Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Employment agrmnt
Quarterly results
Appointed director
Soliton, Inc. (SOLY) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/16/2021 8-K Quarterly results
12/14/2021 8-K Quarterly results
08/06/2021 8-K Other Events
07/20/2021 8-K Submission of Matters to a Vote of Security Holders
07/02/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
04/16/2021 8-K Quarterly results
03/15/2021 8-K Quarterly results
03/04/2021 8-K Quarterly results
02/01/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "Soliton Reports Third Quarter 2020 Results"
11/02/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement between Soliton, Inc. and Brad Hauser",
"Amendment to Amended and Restated Employment Agreement between Soliton, Inc. and Christoper Capelli"
10/26/2020 8-K Appointed a new director
08/11/2020 8-K Quarterly results
07/01/2020 8-K Quarterly results
06/29/2020 8-K Quarterly results
06/22/2020 8-K Quarterly results
06/15/2020 8-K Regulation FD Disclosure, Other Events
Docs: "AAD Slide Presentation",
"Soliton Reports Positive Pivotal Cellulite Clinical Trial Results"
05/14/2020 8-K Quarterly results
04/01/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Soliton Announces New Launch Plan of Next Generation Acoustic Shockwave Product Due to COVID-19 - Expects to Include Tattoo and Cellulite in Launch, Subject to FDA Clearance -"
03/11/2020 8-K Quarterly results
03/03/2020 8-K Quarterly results
03/02/2020 8-K Quarterly results
02/11/2020 8-K Quarterly results
01/27/2020 8-K Regulation FD Disclosure
Docs: "Soliton Announces Positive Data from Extended Keloid and Hypertrophic Scar Trials 12-Week clinical data demonstrates ongoing improvement from single initial treatment; could address market where multiple standard-of-care treatments can see recurrence rates as high as 50%"
11/22/2019 8-K Entry into a Material Definitive Agreement
Docs: "COOPERATIVE DEVELOPMENT ADDENDUM TO ENGINEERING AND DEVELOPMENT SERVICES MASTER AGREEMENT THIS COOPERATIVE DEVELOPMENT ADDENDUM is entered into as of November 20, 2019 and made effective as of July 1, 2019 , by and between SOLITON, INC., a Delaware company, having its principal office at 5304 Ashbrook Drive, Houston, TX 77081 , and EMPHYSYS, INC., a Delaware corporation, having its principal office at 2-X Gill Street, Woburn, Massachusetts 01803 ."
10/15/2019 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Co-Placement Agency Agreement between Soliton, Inc. and Roth Capital Partners, LLC, Boustead Securities, LLC, and Maxim Group LLP",
"Form of Warrant Agreement issued in offering",
"Form of Securities Purchase Agreement by and among Soliton, Inc. and the Investors",
"Form Registration Rights Agreement by and among Soliton, Inc. and the Investors"
09/19/2019 8-K Investor presentation
Docs: "Soliton, Inc. Corporate Slide Presentation September 2019"
09/09/2019 8-K Quarterly results
07/15/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Soliton Announces Positive 26-week Cellulite Clinical Trial Results Demonstrate Long-Term Improvement"
07/01/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/18/2019 8-K Quarterly results
06/04/2019 8-K Investor presentation
Docs: "Soliton, Inc. Corporate Slide Presentation June 2019"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy